Sign in
Taking people in United StatesNo phase

White button mushroom and inflammation in obese postmenopausal women at high breast cancer risk

Tests white button mushroom in obese postmenopausal women at high breast cancer risk.

Key facts

Who runs it
City of Hope Medical Center
Where
Duarte, United StatesSee the site
Trial code
Registry title
Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
Status
Recruiting
People taking part
26 people, planned
Started
27 Jul 2021
Expected to end
12 Jan 2027
Type of study
Interventional
Treatments tested
  • Questionnaire Administration
  • White Button Mushroom Extract
Record updated
5 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for postmenopausal women with a high body mass index and a high risk of breast cancer. They would take white button mushroom powder to study its effect on inflammation and immune cells.

Age
21 years or older
Sex
Women only
Disease stage
Postmenopausal women with BMI >= 30 (Asian BMI >= 25 kg/m^2) and high breast cancer risk (at least 2 times the general population for their age group). Examples: known BRCA1, BRCA2 or p53 mutation, close relatives with breast cancer, earlier biopsy showing atypical hyperplasia or carcinoma in situ in the last 10 years, 5 year Gail risk >= 1.7, or earlier T1 or T2 breast cancer 5 or more years ago.
Earlier treatment
Earlier chemoprevention or adjuvant therapy must have ended 6 or more months before joining. Earlier mushroom supplements must have ended at least 3 months before joining.
Biomarker or test result
Some women qualify through a known gene change linked to hereditary breast cancer, such as BRCA1, BRCA2 or p53. Other women qualify through family history, earlier biopsy results or a Gail score of 1.7 or more. Normal blood counts, liver tests and kidney tests are also needed.

Main reasons for not taking part

  • Cancer in the last 5 years (except non-melanoma skin cancer or cervical carcinoma in situ)
  • Ongoing chemotherapy, radiation or other cancer treatment
  • Bleeding tendency, or using Coumadin or other blood thinners
  • Using hormone-changing medicines or immunosuppressant medicines
  • Premenopausal status, or pregnant or able to have children

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • This study will be conducted in postmenopausal women who have increased risk of breast cancer and high BMI >= 30 kg/m\^2
  • The study population will consist of women with a relative risk of developing breast cancer that is at least > 2 x that of the general population for their age group based on any of the following:; Have a known genetic mutation associated with hereditary breast cancer (including BRCA1, BRCA2, p53, etc.); One or more first degree relatives with breast cancer, with at least one under the age of 60; Two or more second degree relatives with breast cancer, with at least one under the age of 50; Prior biopsy diagnosing atypical lobular hyperplasia, atypical ductal hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ in the last 10 years; Have a Gail Risk Assessment (which is based on age, race, age of menarche, age of first live birth, number of first degree relatives with breast cancer, number of breast biopsies, and presence of high risk histology on any biopsies) that is considered high risk compared to the general population i.e. 5 year Gail >= 1.7; Prior diagnosis of T1 or T2 breast cancer >= 5 years, without antiestrogen therapy for > six months when applicable
  • ELIGIBILITY CRITERIA FOR HIGH RISK PATIENTS FOR THE CLINICAL TRIAL
  • Body mass index (BMI) >= 30 (Asian BMI >= 25 kg/m\^2)
  • Postmenopausal, defined as continuous absence of menstruation for 12+ months, status post bilateral oophorectomy, or status post hysterectomy with follicle stimulating hormone (FSH) in menopausal range
  • Bilateral mammogram within the 12 months prior to study enrollment that is read as not suspicious for breast cancer (American College of Radiology [ACR] class I-III). Subjects with a class IV mammogram may be entered once they have had a negative biopsy. In cases of bilateral mastectomy, documentation that the patient has been continuously without evidence of disease for 5 years will suffice
  • Serum creatinine of 1.5 X upper limit of institutional norm or less
  • Total bilirubin of 1.5 X upper limit of institutional norm or less
  • ALT and aspartate aminotransferase (AST) of less than 2 X upper limit of institutional norm or less
  • Hemoglobin of 9.0 gm/dL or more
  • Platelets of 100,000/mm\^3 or more
  • Total white blood cell (WBC) of 3500/mm\^3
  • Absolute neutrophil count (ANC) of 1500/mm\^3 or more
  • Must be willing to have about 40-50 ml of blood (approximately 8-10 teaspoons) drawn at 0 and 3 months
  • Must be able to swallow pills
  • This study will assess WBM powder in postmenopausal women of 21 years of age or older. Younger women are unlikely to be postmenopausal
  • Participants will have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • The effects of WBM on the developing fetus are unknown. Pregnant and women with childbearing potential are not eligible to participate in this study of postmenopausal women at high risk of breast cancer
  • All subjects must have the ability to understand and the willingness to sign a written informed consent. Participants must be aware of their increased breast cancer risk and willingly consent after being informed of the investigational nature of the intervention, alternatives, potential benefits, side-effects, risks, and discomforts
  • Prior therapies, including chemoprevention or adjuvant therapies, must have been completed for 6 or more months prior to study entry. Prior use of mushroom or mushroom chemical-containing supplements must have been completed within 3 months of study entry

Who cannot take part

  • Concurrent use of hormone-modifying medications including systemic hormone replacement therapy (local vaginal preparations are permitted), selective estrogen receptor modifiers (SERMs), aromatase inhibitors (Ais), or gonadotropic-releasing hormone (GnRH) modifiers within 3 months of randomization
  • Concurrent use of immunosuppressant medications
  • Chronic use of any herbal or dietary supplement containing mushrooms within the 3 months prior to entry on the study
  • Treatment with other investigational agents
  • Subjects on a standing regimen of full dose aspirin (>= 325 mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs) or NSAID-containing products
  • Active malignancy within the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix. NOTE: If there is a history of prior malignancy, the participant must not be receiving other specific treatment, i.e., other hormonal therapy, for their cancer
  • Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
  • History of a bleeding tendency or current use of Coumadin or other anticoagulants
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements
  • Known sensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to WBM or
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Premenopausal status
  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Where in United States

  • City of Hope Medical CenterDuarte, United StatesContact: Lisa D. YeeTaking people

About the trial

What the trial wants to find out

This clinical trial studies the effects of dietary white button mushroom on inflammation (the body's process of fighting against harmful things) and immune cells (white blood cells) in postmenopausal women with both high body mass index or BMI (percentage of body fat) and high risk of breast cancer. The body is in a constant state of alert when inflammation lingers at a low level and becomes chronic, as with having button mushroom is a dietary supplement that may improving responses of immune cells (white blood cells) and decreasing chronic inflammation.

Read full original descriptionShow less

Information gathered from this study may help researchers determine whether white button mushroom have any effects on body fat and breast cancer risk.

The group in the trial

  • Prevention (white button mushroom)Treatment being tested

    Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.

    Treatment: Questionnaire Administration and White Button Mushroom Extract

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
White Button Mushroom and Biomarkers of Immune Cell and Inflammatory Responses in Obese Postmenopausal Women at High Risk of Breast Cancer
Plain-language title
White button mushroom and inflammation in obese postmenopausal women at high breast cancer riskGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 January 2026